Fusion Pharmaceuticals Licenses Isogenica’s CIS Display Technology

By April 18, 2018 No Comments

Technology will be used to progress Fusion’s pipeline of targeted alpha therapeutics for the treatment of cancers

Cambridge, UK and Hamilton, Canada, 18th April 2018: Isogenica Ltd and Fusion Pharmaceuticals Inc (Fusion) today announced a new licensing agreement that will leverage each other’s strengths in recombinant protein technologies and radiopharmaceutical development. Isogenica is a leader in the design and construction of highly diverse synthetic antibody libraries and the use of novel in vitro polypeptide display systems. Fusion is a biopharmaceutical company focused on developing novel targeted alpha therapeutics, or radiopharmaceuticals, for the treatment of cancers.

Under the terms of the agreement, Isogenica has granted a licence to Fusion to utilise its proprietary in vitro CIS Display technology, for the discovery, development and commercialisation of therapeutic products derived from polypeptide libraries generated using this technology. Fusion will use the Isogenica technology to advance its internally developed drug pipeline. Under the terms of the agreement, Isogenica will receive an upfront fee and annual licence payments. If therapeutic products are advanced into development, Isogenica is entitled to additional milestone payments.

Adam Collier, Isogenica’s Director of Commercial Development commented: “This is another very significant deal for Isogenica, which highlights the robustness and utility of the company’s CIS Display technology as an excellent starting point for the rapid and efficient discovery of novel biotherapeutics. We look forward to working closely with Fusion to help their exciting drug discovery strategy to progress.

We are looking forward to the partnership with Isogenica,” said Eric Burak, Fusion’s CSO. “As part of our long-term strategy, Fusion is committed to both identifying our own agents and in-licensing assets that can be transformed into targeted alpha therapeutics. This partnership with Isogenica will help us to advance our internally developed pipeline of drugs while we progress our lead product, FPX-01, into the clinic later this year.”


About Fusion Pharmaceuticals, Inc.

Fusion Pharmaceuticals is a biopharmaceutical company located in Hamilton, Ontario, Canada and Boston, MA, focused on becoming the leader in the targeted alpha therapy field. Fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. In addition to its lead program, FPX-01 with a clinical trial planned for 2018, Fusion is expanding its pipeline of products through a proprietary protein discovery platform, in-licensing targeting molecules, and forming new strategic partnerships.


About Isogenica Ltd

Isogenica is a drug discovery platform-licensing company focusing on the design and build of diverse, fully synthetic, antibody libraries for use in biopharmaceutical discovery. Partners can access an advanced camelid single-domain antibody library (llamdA™) and state-of-the-art, fully synthetic and highly diverse human Fab antibody libraries (Alexandria™). The company uses its proprietary Colibra™ library technology to ensure that the libraries very accurately reflect its advanced designs. Libraries can be screened in various formats, including phage and CIS Display, a proprietary in vitro display technology which maintains the high diversity of the llamdA™ libraries through the discovery process. CIS Display is also available as a stand-alone polypeptide display technology.



Fusion Pharmaceuticals
Lynn Wick